Cusp Overlap for Higher CoreValve Implantation

Implant depth greater than the length of the membranous septum is an independent predictor of permanent pacemaker implantation. Valve implantation 3 to 5 mm below the aortic annulus in a projection coaxial to the device is recommended. The problem is this is rarely in the annular plane of the valve.

Cirugía para mejorar la sobrevida en insuficiencia tricuspidea aislada

Ideal annular plane projection is normally suggested by CT. For CoreValves, correction of parallax was achieved by adding right anterior oblique caudal angulation, which preserves the anatomic annular plane of the native valve and produces an overlap of right and left coronary cusps (cusp overlap).

This differs from manufacturer recommendation to use left anterior oblique angulation. This produces a shallower apparent device depth of 1 to 2 mm.

This technique could enable higher implantation, making the self-expandable valve more competitive in terms of conduction, vs balloon expandable valves. 

The risk of excessively higher implantation with this technique might increase paravalvular regurgitation, or even embolization.  


Read also: Should Total Occlusion Influence on Revascularization Strategy?


Small observational studies on cusp overlap have shown permanent pacemaker implantation rate lower than 5% for CoreValve and no significant increase in leak or device embolization. 

Implantation 3 to 5 mm below the aortic annulus, using a radiographic projection chosen for both the valve and the device can help improve permanent pacemaker implantation rate. 

This should be confirmed by multicenter registries, with special attention to low-risk population. 

CIRCINTERVENTIONS-120-009258free

Original Title Low Rates of Permanent Pacing Are Observed Following Self-Expanding Transcatheter Aortic Valve Replacement Using an Annular Plane Projection for Deployment.

Reference: Anthony D. Pisaniello et al. Circ Cardiovasc Interv. 2021;14:e009258. DOI: 10.1161/CIRCINTERVENTIONS.120.009258.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....